Arcus Casdatifan ARC-20: 15.1-Month PFS vs Belzutifan Moat

Arcus Biosciences (RCUS) closed July 25 at $28.42, valuing the company at $3.57 billion. The stock is down from recent highs, and the bull case rests on a single asset: casdatifan, a follow-on HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC). The Phase 1/1b ARC-20 data looks good. But good data in a crowded market does not guarantee commercial success, and Arcus faces a competitor that already owns this class.

The ARC-20 Data: Real, But Early

The ARC-20 study tested casdatifan monotherapy in 121 patients with heavily pretreated metastatic ccRCC. Most patients had progressed on at least two prior lines of therapy, including both anti-PD-1 and VEGFR tyrosine kinase inhibitors. The updated analysis, presented in 2026 and published in Nature, showed the key results (Arcus press release).

For the 100mg once-daily tablet cohort, median progression-free survival (mPFS) was 15.1 months. The confirmed overall response rate (cORR) was 45%. Disease control rate was 84%. The 12-month PFS rate was 61%. In the pooled analysis across all doses, mPFS was 12.2 months, cORR was 35%, and disease control rate was 81%.

The Nature publication added a biomarker angle. Patients with high HIF-2a tumor IHC staining (25% or more) had significantly longer PFS than those with low staining (p=0.006). High HIF-2a gene signature expression was associated with improved PFS, with a hazard ratio of 0.43 (95% CI 0.21-0.86, p=0.018). This suggests casdatifan’s benefit is linked to HIF-2a biology, which makes biological sense and offers a potential patient selection strategy for Phase 3.

These are encouraging numbers for a late-line population. A 15.1-month median PFS in patients who have failed multiple prior therapies is clinically meaningful. But this is a Phase 1/1b single-arm study. There is no control arm. The real test comes in PEAK-1, the Phase 3 trial evaluating casdatifan plus cabozantinib versus placebo plus cabozantinib in IO-experienced ccRCC (ClinicalTrials.gov NCT07011719).

The Belzutifan Problem

Merck’s Welireg (belzutifan) is the first-in-class HIF-2a inhibitor, already approved in ccRCC. It generated $716 million in 2025 revenue, growing 41% year over year. In Q1 2026, Welireg sales were $199 million, up 45% year over year. Merck’s own estimates suggest the ccRCC opportunity could reach $6.3 billion annually with combination approaches.

The LITESPARK-003 Phase 2 study of belzutifan plus cabozantinib in first-line ccRCC showed a 70% objective response rate and median PFS of 30.3 months. That is the benchmark casdatifan needs to beat. Casdatifan’s 15.1-month PFS is in a later-line, more refractory population, so direct comparison is imperfect. But when casdatifan moves into Phase 3, it will face belzutifan combinations as the standard of care, not just cabozantinib monotherapy.

For a deeper look at Merck’s HIF-2a strategy in RCC, see our analysis of the Welireg plus Lenvima PDUFA. That piece covers the competitive dynamics in RCC that casdatifan must navigate.

The key question for casdatifan is differentiation. Can it show better efficacy than belzutifan, a better safety profile, or activity in patients who have already received belzutifan? The ARC-20 data suggests casdatifan may produce deeper HIF-2a inhibition at lower exposures, which could translate to better efficacy. But “could” is not “did.” The Phase 3 PEAK-1 trial will answer this.

The Collaboration Strategy

Arcus recently announced two collaborations to expand casdatifan’s reach. The first is a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate casdatifan in combination with ivonescimab, an anti-PD-1/VEGF bispecific, in ccRCC. Data is expected by mid-2026. The second is a clinical supply agreement with AVEO Oncology to test casdatifan plus tivozanib versus tivozanib alone in HIF-2a-inhibitor-pretreated patients within the ARC-20 study.

The AVEO deal is the more strategically interesting one. If casdatifan shows activity in patients who have already received belzutifan, it becomes a sequencing option rather than just a direct competitor. In oncology, sequencing matters. Once a drug class is established, the next drug does not need to replace the first. It needs to work after the first fails. That is a lower bar, but a commercially viable one.

The Summit deal pairs casdatifan with ivonescimab, which has its own PDUFA on November 14 for NSCLC. If ivonescimab gets approved, the combination with casdatifan in ccRCC could be a novel dual-targeting approach. But this is early-stage combination exploration, not a registrational trial.

The Valuation Math

Arcus has a $3.57 billion market cap. Q1 2026 revenue was $17 million, down from $33 million in Q4 2025. The company has cash and equivalents that the financials show declining. This is a pre-revenue biotech valued at $3.57 billion on the strength of a single Phase 3 asset.

The analyst consensus price target is approximately $35.75, with HC Wainwright at $45. At $28.42, the stock trades 26% below the consensus target. That suggests Wall Street sees upside, but the range is wide. The bull case assumes casdatifan succeeds in Phase 3, gets approved, and captures meaningful share from belzutifan. The bear case assumes Phase 3 fails or shows only incremental benefit, and the $3.57 billion market cap evaporates.

Compare Arcus to a revenue-generating comp in the same indication. Exelixis (EXEL) markets cabozantinib, the backbone of ccRCC treatment, and generates over $2 billion in annual revenue. Exelixis trades at roughly 4x revenue. Arcus trades at over 200x its current revenue, entirely on pipeline promise. That is the biotech valuation premium: you pay for what the drug could be, not what it is.

The Pipeline Risk

Casdatifan is not Arcus’s only asset, but it is the most valuable one. The company’s pipeline includes domvanalimab (anti-TIGIT), quemliclustat (anti-CD73), and zimberelimab (anti-PD-1). The TIGIT and CD73 programs have faced setbacks. If casdatifan fails in Phase 3, the remaining pipeline does not justify the current market cap.

The specific risk is PEAK-1. This Phase 3 trial is the make-or-break catalyst. If casdatifan plus cabozantinib beats placebo plus cabozantinib on PFS in IO-experienced ccRCC, the stock re-rates higher. If it misses, the stock loses 50% or more. Single-arm Phase 1 data does not guarantee Phase 3 success. The biomarker strategy (enriching for HIF-2a-high patients) could help, but it adds trial complexity.

The safety profile also warrants attention. In ARC-20, Grade 3 or higher anemia occurred in 25% of the 100mg QD tablet cohort and 41% in the pooled analysis. Grade 3 hypoxia occurred in 9% and 11% respectively. These are known on-target effects of HIF-2a inhibition, and belzutifan carries similar safety signals. But in a Phase 3 combination trial with cabozantinib, additive toxicity could become a problem. Cabozantinib itself carries a heavy side-effect profile. If the combination produces dose-limiting toxicity that forces dose reductions, the efficacy advantage shrinks. Watch the Phase 3 safety data closely. A PFS win that comes with a 30% discontinuation rate is a weaker commercial result than a PFS win with manageable toxicity.

Verdict

Casdatifan’s ARC-20 data is legitimate. A 15.1-month median PFS and 45% response rate in late-line ccRCC, with a biomarker strategy that links benefit to HIF-2a biology, gives Arcus a real shot in Phase 3. The Nature publication adds credibility.

But at $3.57 billion, Arcus prices in Phase 3 success. Merck’s belzutifan already generated $716 million in 2025 and is growing 45% year over year. Casdatifan needs to show it is not just another HIF-2a inhibitor, but a better one. The collaborations with Summit and AVEO are smart, but they are exploratory, not registrational.

I would not buy Arcus at $28.42. The risk-reward is poor for a single Phase 3 asset competing against an entrenched incumbent. If PEAK-1 succeeds, the stock goes to $45 or higher. If it fails, the stock goes to $10. A binary outcome with a 2-to-1 upside-downside ratio is not a bet I want to take at current prices. Wait for PEAK-1 data. If the PFS benefit is clear and the safety holds, buy after the readout. You will pay more, but you will own a drug with proven Phase 3 efficacy instead of a Phase 1 promise.

For investors tracking upcoming biotech catalysts, the Q3 2026 FDA calendar covers the binary events that move stocks like Arcus. Casdatifan’s PEAK-1 readout is not on that calendar yet, but when Arcus announces a data timeline, it will be a major catalyst to watch.